{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:26:21Z","timestamp":1787073981805,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:13:40Z","timestamp":1783768420000},"page":"883-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Why Healthcare Providers are Well Positioned to Talk to Patients About Medical Marijuana"],"prefix":"10.1016","volume":"48","author":[{"given":"Christine","family":"Baily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.009_bib0001","unstructured":"Pew Research Center. Legalizing marijuana for medical, recreational use largely favored in US. 2024. Accessed March 10, 2026. https:\/\/www.pewresearch.org\/politics\/2024\/03\/26\/most-americans-favor-legalizing-marijuana-for-medical-recreational-use\/."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0002","unstructured":"Quinnipiac University Poll. (2019). National poll\u2014March 6, 2019 [Press release]. Accessed March 10, 2026. https:\/\/poll.qu.edu\/Poll-Release-Legacy?releaseid=2604."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0003","series-title":"Medical Cannabis by the Numbers","year":"2026"},{"key":"10.1016\/j.clinthera.2026.06.009_bib0004","unstructured":"United States Department of Health and Human Services. Basis for the recommendation to reschedule marijuana into Schedule III of the Controlled Substances Act. 2023. Accessed January 4, 2026. https:\/\/www.whitehouse.gov\/briefing-room\/statements."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0005","unstructured":"US Department of Justice, Office of Public Affairs. Justice department places FDA-approved marijuana products and products containing marijuana subject to a qualifying state-issued license in Schedule III, strengthening medical research while maintaining strict federal controls. 2026. Accessed June 3, 2026. https:\/\/www.justice.gov\/opa\/pr\/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0006","unstructured":"21 U.S.C. \u00a7 353 (addressing prescriptions by physicians). Accessed June 5, 2026. https:\/\/www.govinfo.gov\/content\/pkg\/USCODE-2024-title21\/pdf\/USCODE-2024-title21chap9-subchapV-partA-sec353.pdf."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0007","unstructured":"21 U.S.C. \u00a7 829 (dispensing and prescription requirements for controlled substances). Accessed June 5, 2026. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-II\/part-1306."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0008","unstructured":"Cannabis Control Commission. Guidance for healthcare providers regarding the medical use of marijuana. 2020. Accessed January 4, 2026. https:\/\/www.mass.gov\/doc\/health-care."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0009","unstructured":"Schedules of Controlled Substances, 21 USC 812. 1996. Accessed March 10, 2026. https:\/\/uscode.house.gov\/view.xhtml?req=(title:21%20section:812%20edition:prelim)."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0010","unstructured":"Registration Requirements, 21 USC 823. 2001. Accessed March 10, 2026. https:\/\/uscode.house.gov\/view.xhtml?req=granuleid:USC-prelim-title21-section823&num=0&edition=prelim."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0011","unstructured":"Prohibited Acts A, 21 USC 841. 2026. Accessed March 10, 2026. https:\/\/uscode.house.gov\/view.xhtml?req=(title:21%20section:841%20edition:prelim)."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0012","unstructured":"Ledbetter, D. (2026). Project destigmatize HealTHCare. Accessed June 4, 2026. https:\/\/www.destigmatizehealthcare.org\/."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0013","unstructured":"Definitions relating to controlled substances, 21 CFR \u00a7 1300.01. 1997. Accessed March 10, 2026. https:\/\/www.law.cornell.edu\/cfr\/text\/21\/1300.01."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0014","unstructured":"Conant v. Walters, 309 F.3d 629 (2002)). Accessed March 10, 2026. https:\/\/law.justia.com\/cases\/federal\/appellate-courts\/F3\/309\/629\/506182\/."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0015","unstructured":"State v. Middlekauff, 974 N.W.2d 781 (2022). Accessed March 10, 2026. https:\/\/iowamedicalmarijuana.org\/cases\/state-middlekauff-2022.html."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0016","unstructured":"Lampe JR. Funding limits on federal prosecutions of state-legal medical marijuana. Congressional Research Service. 2024. Accessed March 10, 2026. https:\/\/www.congress.gov\/crs-product\/LSB10694."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0017","unstructured":"United States Courts. Geographic boundaries of United States courts of appeals and United States district courts. United States Courts. 2026. Accessed January 7, 2026. https:\/\/www.uscourts.gov\/file\/document\/us-federal-courts-circuit-map."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0018","unstructured":"United States v. Sirois, 119 F.4th 143, 151\u201352 (1st Cir. 2024). Accessed March 10, 2026. https:\/\/law.justia.com\/cases\/federal\/appellate-courts\/ca1\/23-1721\/23-1721-2024-10-15.html."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0019","unstructured":"United States v McIntosh, 833 F.3d 1163 (9th Cir. 2016). Accessed March 10, 2026. https:\/\/cdn.ca9.uscourts.gov\/datastore\/opinions\/2016\/08\/16\/15-10117.pdf."},{"issue":"5","key":"10.1016\/j.clinthera.2026.06.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030178","article-title":"Association of cannabis use with cardiovascular outcomes among US adults","volume":"13","author":"Jeffers","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"10.1016\/j.clinthera.2026.06.009_bib0021","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.23.02596","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline","volume":"42","author":"Braun","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2026.06.009_bib0022","unstructured":"United States Food and Drug Administration. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). United States Food and Drug Administration. 2024. Accessed March 10, 2026. https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0023","unstructured":"United States Food and Drug Administration. Warning letters for cannabis-derived products. United States Food and Drug Administration. 2025. Accessed March 10, 2026. https:\/\/www.fda.gov\/news-events\/public-health-focus\/warning-letters-cannabis-derived-products."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0024","unstructured":"Virginia State Board of Pharmacy v. Virginia Citizens Consumer Council, 425 U.S. 748 (1976). Accessed March 10, 2026. https:\/\/supreme.justia.com\/cases\/federal\/us\/425\/748\/."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0025","unstructured":"Swinburne M, Bereday H, Schwartz E. Cannabis Advertising and the First Amendment. The Network for Public Health Law. 2024. Accessed July 2, 2026. https:\/\/www.networkforphl.org\/resources\/cannabis-advertising-and-the-first-amendment\/."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0026","unstructured":"Swinburne M, Liu S. State Regulation of Adult-Use Cannabis Advertising. The Network for Public Health Law. 2022. Accessed July 2, 2026. https:\/\/www.networkforphl.org\/resources\/stateregulation-of-adult-use-cannabis-advertising\/."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0027","unstructured":"Cocroft v. Graham, 122 F.4th 176 (5th Circuit). 2024. Accessed March 10, 2026. https:\/\/law.justia.com\/cases\/federal\/appellate-courts\/ca5\/24-60086\/24-60086-2024-11-22.html."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0028","unstructured":"Doctors For Drug Policy Reform. The international intoxicating cannabinoid product symbol. Doctors For Drug Policy Reform. 2021. Accessed March 10, 2026. https:\/\/www.d4dpr.org\/universal-cannabis-symbol."},{"key":"10.1016\/j.clinthera.2026.06.009_bib0029","article-title":"Understanding cannabis hyperemesis syndrome","author":"Weinberg","year":"2025","journal-title":"Psychol Today"},{"issue":"13","key":"10.1016\/j.clinthera.2026.06.009_bib0030","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jama.2025.0097","article-title":"A new legal standard for medical malpractice","volume":"333","author":"Aaron","year":"2025","journal-title":"JAMA"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:33:21Z","timestamp":1787070801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0149291826002225"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why Healthcare Providers are Well Positioned to Talk to Patients About Medical Marijuana","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}